Eine Exkursion der gemeinsamen Baukommission von dbv und VDB nach Rotterdam und Umgebung

Wenn in den vergangenen Jahren die Anforderungen an neue Bibliotheksbauten diskutiert wurden, dann fielen zumeist Begriffe wie „Lernort“ oder „Dritter Ort“. Für die bauliche Entwicklung von Bibliotheken sind dies ohne Frage wichtige Themen. Die Arbeit der gemeinsamen Baukommission von dbv und VDB verdeutlichte jedoch den Bedarf, künftig auch weitere Aspekte näher zu betrachten. Initiativ dazu reiste die gemeinsame Baukommission im Oktober 2019 mit Kolleg*innen fast aller Bundesländer in die Niederlande, um dort unterschiedliche Bibliotheksneu- und -umbauten der letzten Jahre unter jeweils verschiedenen Fragestellungen zu untersuchen

Eine Exkursion der gemeinsamen Baukommission von dbv und VDB nach Rotterdam und Umgebung

Wenn in den vergangenen Jahren die Anforderungen an neue Bibliotheksbauten diskutiert wurden, dann fielen zumeist Begriffe wie „Lernort“ oder „Dritter Ort“. Für die bauliche Entwicklung von Bibliotheken sind dies ohne Frage wichtige Themen. Die Arbeit der gemeinsamen Baukommission von dbv und VDB verdeutlichte jedoch den Bedarf, künftig auch weitere Aspekte näher zu betrachten. Initiativ dazu reiste die gemeinsame Baukommission im Oktober 2019 mit Kolleg*innen fast aller Bundesländer in die Niederlande, um dort unterschiedliche Bibliotheksneu- und -umbauten der letzten Jahre unter jeweils verschiedenen Fragestellungen zu untersuchen.When the requirements for new library buildings have been discussed in recent years, terms such as "place of learning" or "third place" have mostly been mentioned. These are undoubtedly important issues for the structural development of libraries. However, the work of the joint building commission of dbv and VDB made clear the need to take a closer look at other aspects in the future. On the initiative of this, the joint building commission traveled to the Netherlands in October 2019 with colleagues from almost all federal states in order to examine various new library buildings and renovations in recent years, each under a different set of questions

Eine Exkursion der gemeinsamen Baukommission von VDB und dbv nach Rotterdam und Umgebung

Wenn in den vergangenen Jahren die Anforderungen an neue Bibliotheksbauten diskutiert wurden, dann fielen zumeist Begriffe wie „Lernort“ oder „Dritter Ort“. Für die bauliche Entwicklung von Bibliotheken sind dies ohne Frage wichtige Themen. Die Arbeit der gemeinsamen Baukommission von dbv und VDB verdeutlichte jedoch den Bedarf, künftig auch weitere Aspekte näher zu betrachten. Initiativ dazu reiste die gemeinsame Baukommission im Oktober 2019 mit Kolleg*innen fast aller Bundesländer in die Niederlande, um dort unterschiedliche Bibliotheksneu- und -umbauten der letzten Jahre unter jeweils verschiedenen Fragestellungen zu untersuchen

Constructive approach to limiting periodic orbits with exponential and power law dynamics

In dynamical systems limit cycles arise as a result of a Hopf bifurcation, after a control parameter has crossed its critical value. In this study we present a constructive method to produce dissipative dynamics which lead to stable periodic orbits as time grows, with predesigned transient dynamics. Depending on the construction method a) the limiting orbit can be a regular circle, an ellipse or a more complex closed orbit and b) the approach to the limiting orbit can follow an exponential law or a power law. This technique allows to design nonlinear models of dynamical systems with desired (exponential or power law) relaxation properties.Comment: 17 pages, 6 figure

Hybrid APC in Combination With Resection for the Endoscopic Treatment of Neoplastic Barrett's Esophagus: A Prospective, Multicenter Study

INTRODUCTION: The current therapy of neoplastic Barrett's esophagus (BE) consists of endoscopic resection plus ablation, with radiofrequency ablation as the best studied technique. This prospective trial assesses a potential alternative, namely hybrid argon plasma ablation. METHODS: Consecutive patients with neoplastic BE undergoing ablation after curative endoscopic resection (89.6%) or primarily were included into this prospective trial in 9 European centers. Up to 5 ablation sessions were allowed for complete eradication of BE (initial complete eradication of intestinal metaplasia [CE-IM]), by definition including BE-associated neoplasia, documented by 1 negative endoscopy with biopsies. The main outcome was the rate of initial CE-IM in intention-to-treat (ITT) and per-protocol (PP) samples at 2 years. The secondary end points were the rate of recurrence-free cases (sustained CE-IM) documented by negative follow-up endoscopies with biopsies and immediate/delayed adverse events. RESULTS: One hundred fifty-four patients (133 men and 21 women, mean age 64 years) received a mean of 1.2 resection and 2.7 ablation sessions (range 1-5). Initial CE-IM was achieved in 87.2%of 148 cases in the PP analysis (ITT88.4%); initialBE-associated neoplasiawas98.0%.On2-year follow-up of the129successfully treated cases, 70.8% (PP) or 65.9% (ITT) showed sustained CE-IM; recurrences were mostly endoscopynegative biopsy-proven BE epithelium and neoplasia in 3 cases. Adverse events were seen in 6.1%. DISCUSSION: Eradication and recurrence rates of Barrett's intestinal metaplasia and neoplasia by means of hybrid argon plasma coagulation at 2 years seemto be within expected ranges. Final evidence in comparison to radiofrequency ablation can only be provided by a randomized comparative trial

Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting – a 12-month multicenter cohort study from the German early access programResearch in context

Summary: Background: In April 2023, the antisense oligonucleotide tofersen was approved by the U.S. Food and Drug Administration (FDA) for treatment of SOD1-amyotrophic lateral sclerosis (ALS), after a decrease of neurofilament light chain (NfL) levels had been demonstrated. Methods: Between 03/2022 and 04/2023, 24 patients with SOD1-ALS from ten German ALS reference centers were followed-up until the cut-off date for ALS functional rating scale revised (ALSFRS-R), progression rate (loss of ALSFRS-R/month), NfL, phosphorylated neurofilament heavy chain (pNfH) in cerebrospinal fluid (CSF), and adverse events. Findings: During the observation period, median ALSFRS-R decreased from 38.0 (IQR 32.0–42.0) to 35.0 (IQR 29.0–42.0), corresponding to a median progression rate of 0.11 (IQR −0.09 to 0.32) points of ALSFRS-R lost per month. Median serum NfL declined from 78.0 pg/ml (IQR 37.0–147.0 pg/ml; n = 23) to 36.0 pg/ml (IQR 22.0–65.0 pg/ml; n = 23; p = 0.02), median pNfH in CSF from 2226 pg/ml (IQR 1061–6138 pg/ml; n = 18) to 1151 pg/ml (IQR 521–2360 pg/ml; n = 18; p = 0.02). In the CSF, we detected a pleocytosis in 73% of patients (11 of 15) and an intrathecal immunoglobulin synthesis (IgG, IgM, or IgA) in 9 out of 10 patients. Two drug-related serious adverse events were reported. Interpretation: Consistent with the VALOR study and its Open Label Extension (OLE), our results confirm a reduction of NfL serum levels, and moreover show a reduction of pNfH in CSF. The therapy was safe, as no persistent symptoms were observed. Pleocytosis and Ig synthesis in CSF with clinical symptoms related to myeloradiculitis in two patients, indicate the potential of an autoimmune reaction. Funding: No funding was received towards this study

Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol

Background: Amyotrophic lateral sclerosis (ALS) is a chronic neurodegenerative rare disease that affects motor neurons in the brain, brainstem, and spinal cord, resulting in progressive weakness and atrophy of voluntary skeletal muscles. Although much has been achieved in understanding the disease pathogenesis, treatment options are limited, and in Europe, riluzole is the only approved drug. Recently, some other drugs showed minor effects. Methods: The TUDCA-ALS trial is a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The study aims to enroll 320 patients in 25 centers across seven countries in Europe. Enrolled patients are randomized to one of two treatment arms: TUDCA or identical placebo by oral route. The study measures disease progression during the treatment period and compares it to natural progression during a no-treatment run-in phase. Clinical data and specific biomarkers are measured during the trial. The study is coordinated by a consortium composed of leading European ALS centers. Conclusion: This trial is aimed to determine whether TUDCA has a disease-modifying activity in ALS. Demonstration of TUDCA efficacy, combined with the validation of new biomarkers, could advance ALS patient care